Abstract：
Nanoparticles can be engineered for targeted antigen delivery to immune cells and for stimulating an immune response to improve the antigen immunogenicity. This approach is commonly used to develop nanotechnology-based vaccines. In addition, some nanotechnology platforms may be initially designed for drug delivery, but in the course of subsequent characterization, additional immunomodulatory functions may be discovered that can potentially benefit vaccine efficacy. In both of these scenarios, an in vivo proof of concept study to verify the utility of the nanocarrier for improving vaccine efficacy is needed. Here we describe an experimental approach and considerations for designing an animal study to test adjuvant properties of engineered nanomaterials in vivo.
摘要：
纳米颗粒可以被工程化用于将抗原靶向递送至免疫细胞和用于刺激免疫应答以改善抗原免疫原性。这种方法通常用于开发基于纳米技术的疫苗。此外,一些纳米技术平台最初可能是为药物输送而设计的，但是在随后的表征过程中，可以发现额外的免疫调节功能,这些功能可以潜在地有益于疫苗效力.在这两种情况下，需要进行体内概念验证研究，以验证纳米载体在提高疫苗效力方面的实用性。在这里，我们描述了设计动物研究以测试体内工程纳米材料的佐剂特性的实验方法和考虑因素。
